Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05398809 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
A Phase 2 study of Alopecia Areata and Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT05398809 is a Phase 2 study of Alopecia Areata and Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced) that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 70 participants, below the 1,953-participant average among 26 other Alopecia Areata trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05398809, a Phase 2 study of Alopecia Areata and Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a problem of the immune system. In people with APECED, the immune system makes a mistake and attacks the body. Some people with APECED have a type of hair loss called alopecia areata (AA). No drugs are approved to treat AA. Objective: To see if a study drug (ruxolitinib) can help hair regrowth in people with APECED-associated AA and if it can improve other symptoms caused by the immune system s attack to the body. Eligibility: People aged 12 to 65 years with APECED and severe AA. Design: Participants will be in this study for up to 10 months. They will have 5 in-person visits and 6 televisits, each about 4 weeks apart. One in-person visit may be up to a 10-day stay in the hospital. The first in-person visit will include screening. Participants will have a physical exam. They will have blood tests. Photographs may be taken of their skin. They will answer questions about their quality of life. Participants will begin taking the study drug during their hospital stay. They will take the pills by mouth twice a day for 8 months. Researchers may take tissue samples from participants scalp, gums, and lower lip. Participants may provide samples of urine, stool, nail clippings, and saliva. They may have an eye exam and an ultrasound exam of their abdomen. Some tests may be repeated in subsequent in-person visits. In telehealth visits, participants will answer questions about how they are feeling. They will describe and send photos of hair regrowth. They will be asked to have blood drawn and the results sent to the researchers.
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-01-18 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05398809
The ClinicalTrials.gov registry entry for NCT05398809 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,953-participant average among 26 other Alopecia Areata trials with a reported enrollment target (96% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alopecia Areata appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT05398809 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05398809 about?
NCT05398809 is a clinical study titled "Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata". Background: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a problem of the immune system. In people with APECED, the immune system makes a mistake and attacks the body. Some people with APECED have a type of hair loss called alopecia areata (AA). No drugs are approved t...
What is the current status of trial NCT05398809?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2023-01-18. Estimated completion is 2027-12-01.
What conditions does trial NCT05398809 study?
This clinical trial studies the following conditions: Alopecia Areata, Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced).
What interventions are being tested in trial NCT05398809?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT05398809?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05398809 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
RECRUITING · Phase 2
-
Regeneron AA Multicenter (Dupilumab)
RECRUITING · Phase 2
-
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Alopecia Areata
All registered trials for this condition
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.